rongsheng llc quotation

RONGSHENG PETROCHEMICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of chemicals and chemical fibers. The Company’s main products include aromatics, phosphotungstic acid (PTA), polyethylene terephthalate (PET) chips, terylene pre-oriented yarns (POYs), terylene fully drawn yarns (FDYs) and terylene draw textured yarns (DTYs), among others. The Company distributes its products in domestic market and to...More

On September 30, 2020, Rongsheng Petrochemical Co., Ltd. (SZSE:002493) closed the transaction. The company issued 459,242,250 shares at aprice of CNY 17.42 per share for gross proceeds of CNY 7,999,999,995. The transaction included participation from Horizon Kinetics LLC for 60,275,545 shares, existing investor Caitong Fund Management Co., Ltd. for 57,118,254 shares, Hangzhou Fenhua Investment Partnership (Limited Partnership) for 37,887,485 shares, Bank of Communications Schroder Fund Management Co., Ltd. for 33,696,900 shares, Fullgoal Fund Management Co., Ltd. for 30,137,772 shares, Huayi No. 1 Private Equity Securities Investment Fund, a fund managed by Zhejiang Invest Equity Investment & Management Co., Ltd. for 24,684,270 shares, Quanying No. 5 Private Securities Investment Fund, a fund managed by Zhejiang Invest Equity Investment & Management Co., Ltd. for 21,814,006 shares , Shanghai Orient Securities Asset Management Co., Ltd. for 15,154,994 shares, JT Assets Management Co., Ltd. for 14,064,293 shares, Guotai Asset Management Co., Ltd. for 13,490,241 shares, Morgan Stanley & Co. International plc for 13,203,214 shares, Nuode Asset Management Co,. Ltd. for 13,203,214 shares, Bosera Asset Management Co., Ltd. for 13,203,214 shares, Hangzhou Jintou Shengnan Investment Partnership (Limited Partnership) for 20,780,711 shares, Shenzhen Boyi Anying Asset Management Co., Ltd. for 13,203,214 shares, Ningbo Meishan Free Trade Port Zone Junheng Investment Partnership Enterprise (Limited Partnership) for 13,203,214 shares, Qian Xiaomei for 24,110,218 shares, Qiao Xiaohui for 20,206,659 shares and Qi Guohong for 20,091,848 shares. The company has raised net proceeds of CNY 7,959,500,709.86

Rongsheng Petro Chemical Co, Ltd. specialises in the production and marketing of petrochemical and chemical fibres. Products include PTA yarns, fully drawn polyester yarns (FDY), pre-oriented polyester yarns (POY), polyester textured drawn yarns (DTY), polyester filaments and polyethylene terephthalate (PET) slivers.

The major global manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. In 2021, the world"s top three vendors accounted for approximately % of the revenue.

When there were differences in units or testing methods, or the presence of apparently exaggerated numbers, the extracted outcomes were converted to standardized mean difference (SMD) values with the 95% confidence interval (CI) to complete the summary statistics. In other cases, the weighted mean difference (WMD) and 95% CI were adopted. The sample size of an experimental study is usually smaller than of a clinical study. Therefore, Hedge"s g rather than Cohen"s d was implemented. Statistical heterogeneity between studies was calculated using the I squared (I2) statistic. Random effects were selected because of the small sample size and prevalent statistical heterogeneity in preclinical studies. To more accurately explore the effect of group size, prespecified subgroups were assessed by different methods. If heterogeneity was remarkable, subgroup analysis, sensitivity analysis, and/or meta-regression analysis were conducted. If the consistency of baseline data was poor, linear regression and multiple regression were utilized. If the same outcome index was reported by more than 10 articles, funnel plots and the Egger"s test were used to assess publication bias. All quantitative outcomes were analyzed using Stata/SE version 12 (StataCorp LLC, College Station, TX, USA) and RevMan version 5.3 (The Cochrane Collaboration, London, England). A probability value of < 0.05 was considered statistically significant.